Compare GO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GO | OMER |
|---|---|---|
| Founded | 1946 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.8M | 821.7M |
| IPO Year | 2019 | 2008 |
| Metric | GO | OMER |
|---|---|---|
| Price | $5.93 | $11.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $11.30 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 4.1M | 714.8K |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,759,000.00 | $29,868,000.00 |
| Revenue This Year | $8.24 | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.66 | $2.95 |
| 52 Week High | $19.41 | $17.65 |
| Indicator | GO | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 24.27 | 44.69 |
| Support Level | $5.66 | $11.09 |
| Resistance Level | $10.42 | $11.90 |
| Average True Range (ATR) | 0.44 | 0.45 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 5.57 | 19.64 |
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.